SA
OLMA

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 28.2 · elevated volatility

Overview →

Olema Pharmaceuticals is a clinical-stage oncology company developing OP-1250, an oral selective estrogen receptor degrader (SERD) targeting endocrine-resistant breast cancer. The company's lead asset is in Phase 3 trials (OPERA-01) for ER+/HER2- metastatic breast cancer, competing against AstraZeneca's Orserdu and Sanofi's elacestrant. With no revenue and $1.8B market cap following 349% annual return, the stock trades on clinical trial readouts and regulatory milestone expectations.

HealthcareClinical-Stage Oncology Biotechnologyhigh - Fixed R&D costs dominate with minimal variable expenses until commercialization. Clinical trial success creates massive operating leverage as single asset can generate $500M+ annual revenue with incremental manufacturing costs under 20%. However, pre-revenue stage means current burn rate of $100M+ annually with zero revenue creates negative leverage until approval. Commercial launch would require $50-100M sales force investment but then scales efficiently through specialty oncology distribution.

Business Overview

01No current revenue - pre-commercial clinical-stage company
02Future revenue dependent on OP-1250 approval and commercialization (estimated 2027-2028 launch if Phase 3 successful)
03Potential partnership/licensing revenue from ex-US territorial rights

Olema operates a binary outcome model typical of clinical-stage biotechs: invest capital in R&D to advance OP-1250 through FDA approval, then monetize via direct commercialization in oncology specialty channels or partnership deals. The oral SERD market addresses limitations of injectable competitors (Faslodex) with estimated $3-5B peak sales potential in ER+ breast cancer. Pricing power derives from differentiated efficacy/safety profile versus existing SERDs and limited competition in oral formulations. Company burns approximately $100M annually on clinical trials and will require either partnership capital or equity raises to fund commercialization infrastructure.

What Moves the Stock

Phase 3 OPERA-01 trial interim analysis and topline data readouts (primary endpoint: progression-free survival vs comparator)

FDA regulatory interactions including Breakthrough Therapy designation decisions and NDA filing timelines

Clinical data presentations at ASCO, ESMO, and San Antonio Breast Cancer Symposium showing OP-1250 efficacy vs Orserdu/elacestrant

Partnership announcements for ex-US commercialization rights or combination therapy collaborations

Equity financing announcements and cash runway updates given $100M+ annual burn rate

Watch on Earnings
Clinical trial enrollment rates and timeline guidance for OPERA-01 data readoutsCash position and projected runway to key milestones (currently $800M+ cash with 8.03 current ratio suggests 8+ quarters)R&D expense burn rate and headcount expansion signaling commercial preparationRegulatory milestone achievements and FDA feedback on registration strategy

Risk Factors

Single-asset dependency: OP-1250 represents 100% of company value with no diversified pipeline, creating binary Phase 3 trial outcome risk

Competitive intensity in oral SERD market with AstraZeneca (Orserdu approved 2023), Sanofi (elacestrant), and Eli Lilly programs potentially establishing efficacy benchmarks before OPERA-01 readout

Regulatory pathway uncertainty as FDA standards for ER+ breast cancer evolve, particularly regarding comparator arm selection and progression-free survival vs overall survival endpoints

AstraZeneca's Orserdu first-mover advantage in oral SERD market with 2+ year head start on commercial infrastructure and physician adoption

Combination therapy strategies from larger oncology players (Pfizer, Novartis) pairing CDK4/6 inhibitors with next-gen endocrine agents could limit OP-1250 monotherapy market

Biosimilar competition to existing standards of care (fulvestrant) reducing overall SERD pricing umbrella by 2027-2028 launch window

Cash burn of $100M+ annually requires equity financing within 24-30 months absent partnership, creating dilution risk for current shareholders

Pre-revenue valuation of $1.8B implies Phase 3 success already partially priced in, leaving asymmetric downside if trial fails or shows non-differentiated efficacy

Negative 42.5% ROA reflects ongoing cash consumption with no near-term path to profitability until 2028+ commercial launch

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - Clinical trial timelines and FDA approval processes are largely insulated from GDP fluctuations. However, financing environment affects ability to raise capital for trials and commercialization. Oncology drug demand is non-discretionary and recession-resistant, though payer reimbursement negotiations can tighten during economic stress.

Interest Rates

High sensitivity through valuation multiple compression rather than operational impact. Rising rates increase discount rates applied to distant cash flows (2028+ revenue), disproportionately affecting pre-revenue biotechs trading on NPV of pipeline. 10-year Treasury moves directly impact biotech sector multiples. Additionally, higher rates increase cost of future equity raises needed to fund $200M+ commercialization investment. Fed policy shifts can trigger 20-40% sector-wide biotech volatility.

Credit

Minimal direct credit exposure with 0.01 debt/equity ratio and $800M+ cash position. Company funds operations through equity markets rather than debt. However, broader credit market stress affects biotech IPO/follow-on windows and partnership deal structures. High-yield spread widening typically correlates with reduced risk appetite for clinical-stage assets.

Live Conditions
Dow Jones FuturesRussell 2000 FuturesS&P 500 Futures

Profile

growth/momentum - Attracts high-risk biotech specialists and event-driven funds focused on binary clinical catalysts. The 349% one-year return and 165% three-month surge indicates momentum-driven trading around trial milestones. Institutional ownership likely concentrated in healthcare-focused hedge funds and biotech ETFs rather than broad index funds. Not suitable for income or value investors given no revenue, negative cash flow, and valuation based entirely on discounted future earnings 3-5 years out.

high - Clinical-stage single-asset biotechs exhibit extreme volatility around data readouts, with 30-50% single-day moves common on trial results. Recent 310% six-month return demonstrates momentum volatility. Beta likely exceeds 2.0 relative to broader market. Stock trades on binary outcomes rather than incremental fundamentals, creating option-like payoff structure inappropriate for risk-averse portfolios.

Key Metrics to Watch
OPERA-01 Phase 3 trial enrollment completion and interim analysis timing announcements
Objective response rate and progression-free survival data vs Orserdu in head-to-head comparisons
Cash and equivalents balance relative to quarterly burn rate (currently 8.03 current ratio suggests strong liquidity)
Biotech sector financing environment and comparable deal valuations for late-stage oncology assets
FDA Breakthrough Therapy or Fast Track designation status updates
Partnership deal structures in ER+ breast cancer space indicating market valuation of oral SERDs
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.